Trial Profile
A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck (originally EMR 62241-508) and in Patients With EGFR-expressing, KRAS wild-type Metastatic Colorectal Cancer (originally EMR 62202-509)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Antineoplastics
- Indications Colorectal cancer; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Registrational
- Sponsors Merck KGaA
- 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov records (NCT01075828 and NCT01082315).
- 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov records (NCT01075828 and NCT01082315).
- 01 Mar 2013 Planned end date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record (NCT01075828).